FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1488333493> ?p ?o ?g. }

• W1488333493 endingPage "55" @default.
• W1488333493 startingPage "948" @default.
• W1488333493 abstract "The effect of i.v. administration of the nitric oxide synthase (NOS) inhibitor N(omega)-nitro-L-arginine (L-NNA) on tumor blood flow compared with normal tissue blood flow was studied in anesthetized BD9 rats bearing subcutaneous P22 carcinosarcomas. Blood flow was measured by the tissue uptake of radiolabeled iodoantipyrine. The reversibility of blood flow changes was tested by subsequent administration of L-arginine, the natural substrate for NOS. The effect of L-NNA was compared to that of the imidazolineoxyl N-oxide C-PTIO, a carboxyl derivative of 2-phenyl-4,4,5,5,-tetramethylimidazoline-1-oxyl-3-oxide and a nitric oxide scavenger. Drug-induced changes in mean arterial blood pressure (MABP) were monitored and used to calculate relative drug-induced changes in tissue vascular resistance. Heart rate was measured from blood pressure traces. L-NNA significantly decreased heart rate and increased MABP in a dose-dependent manner. Significant dose-dependent reductions in blood flow with L-NNA were observed in tumor, skeletal muscle, spleen, and skin overlying the tumor. No significant effect was found for normal skin, brain, heart, kidney, and small intestine. At 1 mg/kg, the effect of L-NNA was selective for the tumor, with a significant decrease in tumor blood flow to 0.45 of the control level and no significant effect in any of the normal tissues. Higher doses did not produce any further reduction in tumor blood flow, presumably due to an increase in tumor perfusion pressure arising from the increase in MABP at these doses. Vascular resistance was increased to some extent in all of the tissues studied but, overall, was greatest in the tumor. At 1 mg/kg, there was a 2-2.5-fold increase in tumor vascular resistance but no significant increase in any of the normal tissues. At the highest dose used (10 mg/kg), the increases in vascular resistance in the skeletal muscle and spleen were equivalent to that in the tumor. Administration of L-arginine 15 min after L-NNA completely reversed the decrease in tumor blood flow observed for 1 mg/kg L-NNA alone. In contrast to the effect of L-NNA, constant i.v. infusion of C-PTIO had no effect on tumor or normal tissue blood flow. These results indicate that nitric oxide is important for maintaining a vasodilatory tone in tumors and that inhibition of NOS may provide a means for enhancing therapeutic regimens that would benefit from a selective reduction in tumor blood flow." @default.
• W1488333493 created "2016-06-24" @default.
• W1488333493 creator A5018041476 @default.
• W1488333493 creator A5025383945 @default.
• W1488333493 creator A5044806410 @default.
• W1488333493 date "1997-03-01" @default.
• W1488333493 modified "2023-09-29" @default.
• W1488333493 title "Inhibition of nitric oxide synthase induces a selective reduction in tumor blood flow that is reversible with L-arginine." @default.
• W1488333493 cites W1545107665 @default.
• W1488333493 cites W1803915068 @default.
• W1488333493 cites W1851718973 @default.
• W1488333493 cites W1929009802 @default.
• W1488333493 cites W1970127379 @default.
• W1488333493 cites W1980382844 @default.
• W1488333493 cites W1985473430 @default.
• W1488333493 cites W1986774826 @default.
• W1488333493 cites W1986812997 @default.
• W1488333493 cites W1987971711 @default.
• W1488333493 cites W1989461154 @default.
• W1488333493 cites W1996616962 @default.
• W1488333493 cites W2000258847 @default.
• W1488333493 cites W2001878542 @default.
• W1488333493 cites W2009953484 @default.
• W1488333493 cites W2015447656 @default.
• W1488333493 cites W2026417622 @default.
• W1488333493 cites W2029491963 @default.
• W1488333493 cites W2038181981 @default.
• W1488333493 cites W2042196624 @default.
• W1488333493 cites W2045843142 @default.
• W1488333493 cites W2051344336 @default.
• W1488333493 cites W2052953255 @default.
• W1488333493 cites W2069072174 @default.
• W1488333493 cites W2072527651 @default.
• W1488333493 cites W2076257266 @default.
• W1488333493 cites W2082849691 @default.
• W1488333493 cites W2089901009 @default.
• W1488333493 cites W2099048452 @default.
• W1488333493 cites W2112617686 @default.
• W1488333493 cites W2121731045 @default.
• W1488333493 cites W2141059616 @default.
• W1488333493 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9041200" @default.
• W1488333493 hasPublicationYear "1997" @default.
• W1488333493 type Work @default.
• W1488333493 sameAs 1488333493 @default.
• W1488333493 citedByCount "31" @default.
• W1488333493 countsByYear W14883334932013 @default.
• W1488333493 countsByYear W14883334932015 @default.
• W1488333493 countsByYear W14883334932016 @default.
• W1488333493 countsByYear W14883334932017 @default.
• W1488333493 countsByYear W14883334932022 @default.
• W1488333493 crossrefType "journal-article" @default.
• W1488333493 hasAuthorship W1488333493A5018041476 @default.
• W1488333493 hasAuthorship W1488333493A5025383945 @default.
• W1488333493 hasAuthorship W1488333493A5044806410 @default.
• W1488333493 hasConcept C120770815 @default.
• W1488333493 hasConcept C126322002 @default.
• W1488333493 hasConcept C134018914 @default.
• W1488333493 hasConcept C146957229 @default.
• W1488333493 hasConcept C158846371 @default.
• W1488333493 hasConcept C178853913 @default.
• W1488333493 hasConcept C185592680 @default.
• W1488333493 hasConcept C2777468819 @default.
• W1488333493 hasConcept C2777622882 @default.
• W1488333493 hasConcept C2778010969 @default.
• W1488333493 hasConcept C2780091579 @default.
• W1488333493 hasConcept C515207424 @default.
• W1488333493 hasConcept C519581460 @default.
• W1488333493 hasConcept C55493867 @default.
• W1488333493 hasConcept C58245268 @default.
• W1488333493 hasConcept C71924100 @default.
• W1488333493 hasConcept C84393581 @default.
• W1488333493 hasConceptScore W1488333493C120770815 @default.
• W1488333493 hasConceptScore W1488333493C126322002 @default.
• W1488333493 hasConceptScore W1488333493C134018914 @default.
• W1488333493 hasConceptScore W1488333493C146957229 @default.
• W1488333493 hasConceptScore W1488333493C158846371 @default.
• W1488333493 hasConceptScore W1488333493C178853913 @default.
• W1488333493 hasConceptScore W1488333493C185592680 @default.
• W1488333493 hasConceptScore W1488333493C2777468819 @default.
• W1488333493 hasConceptScore W1488333493C2777622882 @default.
• W1488333493 hasConceptScore W1488333493C2778010969 @default.
• W1488333493 hasConceptScore W1488333493C2780091579 @default.
• W1488333493 hasConceptScore W1488333493C515207424 @default.
• W1488333493 hasConceptScore W1488333493C519581460 @default.
• W1488333493 hasConceptScore W1488333493C55493867 @default.
• W1488333493 hasConceptScore W1488333493C58245268 @default.
• W1488333493 hasConceptScore W1488333493C71924100 @default.
• W1488333493 hasConceptScore W1488333493C84393581 @default.
• W1488333493 hasIssue "5" @default.
• W1488333493 hasLocation W14883334931 @default.
• W1488333493 hasOpenAccess W1488333493 @default.
• W1488333493 hasPrimaryLocation W14883334931 @default.
• W1488333493 hasRelatedWork W1488333493 @default.
• W1488333493 hasRelatedWork W1623258072 @default.
• W1488333493 hasRelatedWork W1989830998 @default.
• W1488333493 hasRelatedWork W2000124518 @default.
• W1488333493 hasRelatedWork W2026404744 @default.
• W1488333493 hasRelatedWork W2053521426 @default.

• next